Tuesday, August 25, 2026
60 articles analyzed
Updated Aug 25, 1:24 AM · 60 sources analyzed
Key Takeaways
A novel CD28-selective small molecule shows preclinical IBD activity without blocking CTLA-4 — a genuine mechanistic advance if it holds in humans.
Pharvaris's Phase 2 HAE prophylaxis study terminated with no explanation, a red flag for its competitive position against oral rivals.
Multiple Phase 3 completions logged today — Viridian TED, Camurus acromegaly, Enanta RSV — but zero efficacy data released; data events still ahead.
🏆 Winner
Viridian Therapeutics — completion of both its Phase 3 pivotal and open-label extension in thyroid eye disease sets the stage for a potential BLA filing against a high-value market.
📉 Loser
Pharvaris — termination of its Phase 2 oral HAE prophylaxis study without explanation undermines confidence in its ability to compete in a rapidly advancing competitive field.
🔭 Watch Next
Enanta Pharmaceuticals' Phase 2b EDP-938 topline efficacy data in high-risk RSV adults are the most consequential near-term readout visible from today's registry completions, with results expected in H2 2026.
CD28 inhibitor shows IBD signal in preclinical work
Researchers published a bioRxiv preprint describing a small molecule that selectively blocks CD28 costimulation — a key signal that amplifies pathogenic T-cell activity — without disrupting the CTLA-4 brake on immune responses, a limitation of current biologics like abatacept. The compound was identified using a split-luciferase screening platform and showed restraint of inflammatory T-cell responses in IBD models. If the selectivity profile holds in humans, this approach could offer a cleaner immunological intervention than existing B7-pathway agents, with implications for the crowded but mechanistically constrained IBD drug market.
bioRxiv ↗Eli Lilly and Company (DICE Therapeutics subsidiary)
LY4100511 (DC-853) in Moderate-to-Severe Plaque Psoriasis
ClinicalTrials.gov registry record for the Phase 2 study of LY4100511 in moderate-to-severe plaque psoriasis (NCT06602219) has been updated to Completed status. No efficacy or safety data have been disclosed through this registry update.
Why it matters
Lilly acquired DICE specifically for this oral IL-17 platform, so Phase 2 data will be closely scrutinized against PASI score benchmarks set by approved biologics. The absence of any disclosed numbers from this registry update means the market cannot yet assess whether the oral route of administration comes with an efficacy trade-off.
What to watch
Watch for Lilly to release LY4100511 Phase 2 efficacy and safety data at a dermatology congress or in a company pipeline update, likely in H2 2026 or early 2027.
Pharvaris
PHA-022121 (deucrictibant) in Hereditary Angioedema Type I or II (prophylaxis)
The Phase 2 dose-ranging prophylaxis study of oral PHA-022121 in hereditary angioedema (HAE) Type I or II (NCT05047185) has been updated to Terminated status on ClinicalTrials.gov. No efficacy or safety data and no reason for termination were disclosed in the registry record.
Why it matters
A terminated Phase 2 prophylaxis study without explanation is a yellow flag — it could reflect a portfolio prioritization decision, enrollment difficulty, or a safety signal. Investors will want clarification from management on whether the on-demand program remains intact and whether this reflects any mechanistic concern with the bradykinin B2 receptor antagonist approach in the prophylaxis setting.
What to watch
Watch for a Pharvaris corporate update or SEC filing disclosing the reason for termination and the status of its on-demand HAE program in 2026.
Enanta Pharmaceuticals
EDP-938 in RSV infection in high-risk non-hospitalized adults
The Phase 2b randomized, double-blind, placebo-controlled study of oral EDP-938 in high-risk adults with confirmed RSV infection (NCT05568706) has been updated to Completed status. No efficacy or safety data were disclosed in this registry update.
Why it matters
Enanta is in a difficult financial position following prior clinical setbacks, making the EDP-938 data readout a potentially pivotal event for the company's pipeline story. Investors need to see effect size on symptom endpoints — statistical significance without meaningful clinical benefit will not move the needle in a crowded respiratory antiviral space.
What to watch
Watch for Enanta to release Phase 2b topline efficacy data for EDP-938, including symptom score reductions and viral load outcomes, likely in H2 2026.
Selective CD28 small molecule inhibitor restrains IBD T-cell pathology without blocking CTLA-4
A preprint on bioRxiv reports that a novel small molecule identified via split-luciferase screening selectively inhibits CD28 costimulation — amplifying signal for T-cell activation — while leaving CTLA-4 signaling intact, reducing pathogenic T-cell responses in IBD models.
Why it matters
This is preclinical work from a preprint — not peer-reviewed — so caution is warranted, but the mechanistic differentiation from existing B7-pathway agents is scientifically compelling. Companies or investors watching the oral small molecule immunology space in IBD should track whether this compound or the platform attracts pharma partnership interest.
What to watch
Watch for peer-reviewed publication and any disclosure of the compound's developer identity or early IND-enabling studies, which would signal progression toward clinical testing.
ClinicalTrials.gov records for both the Phase 3 pivotal study (NCT05176639) and the open-label extension for non-responders (NCT06179875) have been updated to Completed status. No efficacy or safety data have been released via these registry updates.
Why it matters
Completion of both the Phase 3 and its non-responder extension positions Viridian for a potential regulatory filing in thyroid eye disease, a market currently anchored by Amgen/Horizon's teprotumumab (Tepezza).
Analysis
Registry completion alone tells investors nothing about whether veligrotug matched or beat teprotumumab on proptosis reduction — the bar that actually matters commercially. The next move is a company press release or medical meeting presentation with full efficacy and safety data, which will determine whether Viridian can credibly challenge Tepezza's dominance.
What to watch
Watch for Viridian's topline data announcement and any BLA filing timeline disclosure, expected in the near term following Phase 3 completion.
ClinicalTrials.gov registry record for the Phase 2 study of LY4100511 in moderate-to-severe plaque psoriasis (NCT06602219) has been updated to Completed status. No efficacy or safety data have been disclosed through this registry update.
Why it matters
LY4100511 is an oral IL-17 receptor antagonist — a mechanistic class that, if validated, could compete with injectable biologics like secukinumab and ixekizumab in psoriasis; completion of Phase 2 is a prerequisite to any Phase 3 decision.
Analysis
Lilly acquired DICE specifically for this oral IL-17 platform, so Phase 2 data will be closely scrutinized against PASI score benchmarks set by approved biologics. The absence of any disclosed numbers from this registry update means the market cannot yet assess whether the oral route of administration comes with an efficacy trade-off.
What to watch
Watch for Lilly to release LY4100511 Phase 2 efficacy and safety data at a dermatology congress or in a company pipeline update, likely in H2 2026 or early 2027.
The Phase 3 registry record for CAM2029 in acromegaly (NCT04076462) has been updated to Completed status. No efficacy or safety data were disclosed in this registry update.
Why it matters
CAM2029 is Camurus's long-acting subcutaneous formulation of octreotide targeting a market dominated by monthly intramuscular injections; a successful data readout could support regulatory filings in both acromegaly and additional somatostatin-sensitive indications.
Analysis
Camurus has already received regulatory approvals for CAM2029 in some markets, so this Phase 3 completion likely feeds into label expansion or additional regulatory submission strategies rather than representing a make-or-break moment — but full data publication will be important for physicians comparing it to existing depot formulations.
What to watch
Watch for Camurus to publish or present full Phase 3 efficacy data, including IGF-1 normalization rates and safety profile, at an endocrinology congress in late 2026.
The Phase 2 dose-ranging prophylaxis study of oral PHA-022121 in hereditary angioedema (HAE) Type I or II (NCT05047185) has been updated to Terminated status on ClinicalTrials.gov. No efficacy or safety data and no reason for termination were disclosed in the registry record.
Why it matters
Termination of the prophylaxis study is a potential setback for Pharvaris in the competitive HAE market, where oral prophylaxis options from Kalvista and Intellia are also in development.
Analysis
A terminated Phase 2 prophylaxis study without explanation is a yellow flag — it could reflect a portfolio prioritization decision, enrollment difficulty, or a safety signal. Investors will want clarification from management on whether the on-demand program remains intact and whether this reflects any mechanistic concern with the bradykinin B2 receptor antagonist approach in the prophylaxis setting.
What to watch
Watch for a Pharvaris corporate update or SEC filing disclosing the reason for termination and the status of its on-demand HAE program in 2026.
The Phase 2b randomized, double-blind, placebo-controlled study of oral EDP-938 in high-risk adults with confirmed RSV infection (NCT05568706) has been updated to Completed status. No efficacy or safety data were disclosed in this registry update.
Why it matters
The RSV antiviral adult market remains largely open beyond prophylactic antibodies like nirsevimab; if EDP-938 shows meaningful symptom reduction and viral load suppression, it could establish Enanta in a commercially viable niche.
Analysis
Enanta is in a difficult financial position following prior clinical setbacks, making the EDP-938 data readout a potentially pivotal event for the company's pipeline story. Investors need to see effect size on symptom endpoints — statistical significance without meaningful clinical benefit will not move the needle in a crowded respiratory antiviral space.
What to watch
Watch for Enanta to release Phase 2b topline efficacy data for EDP-938, including symptom score reductions and viral load outcomes, likely in H2 2026.
Selective CD28 small molecule inhibitor restrains IBD T-cell pathology without blocking CTLA-4
A preprint on bioRxiv reports that a novel small molecule identified via split-luciferase screening selectively inhibits CD28 costimulation — amplifying signal for T-cell activation — while leaving CTLA-4 signaling intact, reducing pathogenic T-cell responses in IBD models.
Why it matters
Current biologics targeting the B7-CD28 axis (e.g., abatacept) also suppress CTLA-4, an immune checkpoint, which limits their use; a selective CD28 inhibitor could offer immunosuppression with a cleaner safety profile, expanding the druggable space in IBD and other T-cell-driven autoimmune diseases.
Analysis
This is preclinical work from a preprint — not peer-reviewed — so caution is warranted, but the mechanistic differentiation from existing B7-pathway agents is scientifically compelling. Companies or investors watching the oral small molecule immunology space in IBD should track whether this compound or the platform attracts pharma partnership interest.
What to watch
Watch for peer-reviewed publication and any disclosure of the compound's developer identity or early IND-enabling studies, which would signal progression toward clinical testing.
AbbVie's emraclidine (CVL-231) long-term safety study in schizophrenia terminated
ClinicalTrials.gov shows the Phase 2 long-term safety and tolerability extension study of emraclidine (CVL-231), AbbVie's M4 muscarinic receptor agonist for schizophrenia, was terminated (NCT05443724); no reason or data were disclosed in the registry record.
Why it matters
Emraclidine had generated attention as a non-dopaminergic mechanism for schizophrenia — a differentiated approach — making any termination of a safety extension study a signal worth monitoring for the broader muscarinic agonist field, including competitors like Karuna/BMS's KarXT (xanomeline-trospium).
Analysis
The termination of a long-term safety study without explanation introduces uncertainty about emraclidine's development trajectory at AbbVie; given that KarXT has already reached the market, AbbVie's window for a meaningful first- or second-mover position in muscarinic schizophrenia therapy is narrowing and this development does not help.
What to watch
Watch for an AbbVie pipeline update or investor call disclosing the reason for termination and any revised development plan for emraclidine in schizophrenia or other psychiatric indications.
Brexucabtagene autoleucel Phase 2 cohort 3 in relapsed/refractory mantle cell lymphoma completed
ClinicalTrials.gov registry record for Kite/Gilead's Phase 2 Cohort 3 study of brexucabtagene autoleucel (KTE-X19) in relapsed/refractory mantle cell lymphoma (NCT04880434) has been updated to Completed; no outcome data were disclosed in the registry update.
Why it matters
Brexucabtagene autoleucel (Tecartus) is already approved in mantle cell lymphoma; Cohort 3 data — when released — could inform label refinement or support use in additional patient subgroups, including those previously treated with BTK inhibitors.
Analysis
This is a registry housekeeping update rather than a data event, but it signals that a dataset exists and could be presented at a hematology conference such as ASH 2026. The competitive CAR-T landscape in MCL is intensifying, and Kite will want these data in the public domain to defend market share.
What to watch
Watch for Cohort 3 efficacy and safety data from KTE-X19 in MCL to be presented at ASH 2026 (December) or published in a peer-reviewed journal.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
Erasca filed an 8-K with the SEC disclosing Item 8.01 on August 24, 2026. The filing type and item code suggest a non-routine corporate disclosure, though the specific content was not detailed in the available summary.
SEC EDGAR ↗Every weekday morning
Start your morning with the stories moving biotech.
Clinical readouts · FDA watch · Deal flow · Pipeline pulse